Stockholm, November 6th, 2020 – Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol phenylbutyrate) indicated for the treatment of Urea Cycle Disorders (UCD), in Japan from Horizon Therapeutics plc (Nasdaq: HZNP) (Horizon). As part of the transaction, Horizon’s existing distribution agreement with Japanese rare disease company, Orphan Pacific, will be assigned to Immedica. Orphan Pacific currently markets Buphenyl® in Japan.
The transaction encompasses all IP as well as commercial and distribution rights for the two products in Japan. In combination with Immedica’s previous deal with Horizon (December 2018), Immedica now has rights to the products in all regions outside of North America.
Buphenyl® has in Japan been a reference product for many years in patients suffering from UCD.
“This is an excellent addition to our geographic growth and further strengthens us in the field of UCD treatments. We are truly happy to long-term being able to bring important treatments to patients in Japan suffering from UCD” says Anders Edvell, MD, PhD and CEO of Immedica.
About Urea Cycle Disorders (UCD)
The urea cycle is a process in which waste (ammonia) is removed from the body. When you eat proteins, the body breaks them down into amino acids. Ammonia is produced from leftover amino acids, and it must be removed from the body.
Several inherited conditions can cause problems with this waste-removal process. People with a urea cycle disorder are missing a gene that makes the enzymes needed to break down ammonia in the body. As a group, these disorders occur in 1 in 30,000 newborns. Typically, symptoms such as confusion, nausea, vomiting, decreased food intake and increased sleepiness occur within the first week after birth.
Immedica is a fast-growing private European niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has pan-European and Middle East commercial coverage. In addition, Immedica provides some of its products to other parts of the world via a network of regional distributors.
Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, and product distribution.
Anders Edvell – Chief Executive Officer. email@example.com Phone: +46 705446126